The project Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome (PREDI-LYNCH) is coordinated by Oslo University Hospital (OUH), has received EUR 13.6 million in funding from the European Union HORIZON-MISS-2024-CANCER-01-03 mission on cancer.

An urgent need to improve screening

The project aims to address the unmet need for an accurate, non-invasive, acceptable, and cost-effective method of detecting early-stage cancers in individuals with LS. Approximately 1 in 440 people of European ancestry are affected by LS, which is a hereditary genetic condition that increases the risk of developing cancer at an early age. It specifically increases the odds of colorectal, gynaecological, and urothelial cancers. With only 5% of the 2 million estimated LS carriers in Europe under cancer surveillance, there is an urgent need to improve cancer screening and monitoring.

6-year project

Initiated on 1st May 2025 and coordinated by OUH, the ambitious PREDI-LYNCH project will see the cooperation between Elypta, OUH, and 26 other project partners, bringing together European oncology experts, biotechnology companies, and LS patient advocates. The 6-year project will evaluate multiple promising, non-invasive, liquid biopsy-based technologies in conjunction with artificial intelligence solutions for detecting early-stage cancers and deliver a multi-omic solution for affordable, accessible, and effective heritable cancer detection in LS. 

GAGomes

Elypta will contribute its liquid biopsy tests for the early detection of cancers, based on the profiles of metabolomic glycosaminoglycans (GAGomes) as biomarkers in both plasma and urine, with the aim of stratifying at-risk LS carriers and detecting precancerous and early cancerous lesions. 

“There is a clear and urgent need to improve cancer detection for Lynch Syndrome, and the PREDI-LYNCH project is designed to make a true difference in the lives of LS carriers. Elypta is honoured and excited to be a main contributing partner in this important project. We look forward to combining the results from Elypta’s GAG-based biomarker tests with the consortium’s expertise,” says Marianna Mirabelli, Director of Clinical Development at Elypta.